David J Peace (David Peace)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Chronic Kidney Disease

Prognostic Factors

Patient Reported Outcomes

Top Venues

Nature communications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Yousef Zakharia, Eric A Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David J Peace, Veera Baladandayuthapani, Annesha Majumdar, Xiong Li, Claudia Lalancette, Ilona Kryczek, Weiping Zou, Ajjai Alva
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nature communications 15 (1) (2024)
Yousef Zakharia, Eric A Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David J Peace, Veera Baladandayuthapani, Annesha Majumdar, Xiong Li, Claudia Lalancette, Ilona Kryczek, Weiping Zou, Ajjai Alva
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nature communications 15 (1) (2024)
Yousef Zakharia, Eric A Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David J Peace, Veera Baladandayuthapani, Annesha Majumdar, Xiong Li, Claudia Lalancette, Ilona Kryczek, Weiping Zou, Ajjai Alva
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nature communications 15 (1) (2024)
Yousef Zakharia, Eric A Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David J Peace, Veera Baladandayuthapani, Annesha Majumdar, Xiong Li, Claudia Lalancette, Ilona Kryczek, Weiping Zou, Ajjai Alva
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nature communications 15 (1) (2024)
Yousef Zakharia, Eric A Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David J Peace, Veera Baladandayuthapani, Annesha Majumdar, Xiong Li, Claudia Lalancette, Ilona Kryczek, Weiping Zou, Ajjai Alva
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nature communications 15 (1) (2024)
Michael B Atkins, Opeyemi A Jagede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark N Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael E Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David A Braun, David J Einstein, Paul J Catalano, Hans Hammers
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (25) (2022)
Adam J Olszewski, Lasse Hjort Kyneb Jakobsen, Graham P Collins, Kate Cwynarski, Veronika Bachanova, Kristie A Blum, Kirsten M Boughan, Mark Bower, Alessia Dalla Pria, Alexey Danilov, Kevin A David, Catherine S Diefenbach, Fredrik Ellin, Narendranath Epperla, Umar Farooq, Tatyana A Feldman, Alina S Gerrie, Deepa Jagadeesh, Manali Kamdar, Reem Karmali, Shireen Kassam, Vaishalee P Kenkre, Nadia Khan, Seo-Hyun Kim, Andreas K Klein, Izidore S Lossos, Matthew A Lunning, Peter Martin, Nicolás Martinez-Calle, Silvia Montoto, Seema Naik, Neil Palmisiano, David J Peace, Elizabeth H Phillips, Tycel Jovelle Phillips, Craig A Portell, Nishitha M Reddy, Anna Santarsieri, Maryam Sarraf Yazdy, Knut B Smeland, Scott E Smith, Stephen Douglas Smith, Suchitra Sundaram, Adam Stephen Zayac, Xiao-Yin Zhang, Catherine Zhu, Chan Yoon Y Cheah, Tarec C El-Galaly, Andrew M Evens
Burkitt Lymphoma International Prognostic Index. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (10) (2021)